European Pharma and Biotech Looking Outside EU for Funding
November 10, 2015.
The European Union remains a "powerhouse of innovation" for biotech and pharma, but mostly looks the the US for funding, according to a new report from BioPharm Insight.
Fuelling the growth of EU Pharma and Biotech states that
Although trials have dropped by 24% since 2010, sector innovation is high, led by innovations in oncology drugs, neurological agents and gene therapy treatments.
Deal activity is up in 2015 to date, with increasing interest from European investors; however, three out of top five IPOs listed outside the EU.
Deeper pools of capital and specialist investors are key factors attracting biotech and pharma to US for funding.
EU biotechs are exploring a wide spectrum of funding opportunities, including crowdfunding, grant funding and secondary listings.
